1. Home
  2. DGII vs ANIP Comparison

DGII vs ANIP Comparison

Compare DGII & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digi International Inc.

DGII

Digi International Inc.

N/A

Current Price

$49.61

Market Cap

1.7B

Sector

Technology

ML Signal

N/A

ANIP

ANI Pharmaceuticals Inc.

N/A

Current Price

$74.66

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DGII
ANIP
Founded
1985
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
1995
1999

Fundamental Metrics

Financial Performance
Metric
DGII
ANIP
Price
$49.61
$74.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$48.80
$107.33
AVG Volume (30 Days)
277.4K
318.7K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
77.05
419.23
EPS
0.31
3.32
Revenue
$430,221,000.00
$206,547,000.00
Revenue This Year
$18.71
$19.88
Revenue Next Year
$7.22
$15.77
P/E Ratio
$157.31
$22.35
Revenue Growth
1.46
2.47
52 Week Low
$22.39
$56.71
52 Week High
$51.78
$99.50

Technical Indicators

Market Signals
Indicator
DGII
ANIP
Relative Strength Index (RSI) 56.47 41.34
Support Level $47.00 $74.28
Resistance Level $51.78 $85.12
Average True Range (ATR) 1.96 2.61
MACD -0.13 -0.05
Stochastic Oscillator 57.38 31.01

Price Performance

Historical Comparison
DGII
ANIP

About DGII Digi International Inc.

Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: